Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT03915444Phase 2Completed
- Sponsor
- HonorHealth Research Institute
- Start
- Jul 2019
- Primary completion
- May 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, Cisplatin micelle injection (HA132) and gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by HonorHealth Research Institute. Primary endpoint: Overall Survival at 12 months. Started Jul 2019; status: completed.
02
Drugs
paclitaxelCisplatin micelle injection (HA132)gemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03915444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915444.